Evidence map›Paper›PMID 22174977›Full record

ArticleToxins2011

Llama-derived single domain antibodies specific for Abrus agglutinin.

Ellen R Goldman, George P Anderson, Dan Zabetakis, Scott Walper, Jinny L Liu, Rachael Bernstein, Alena Calm, James P Carney, Thomas W O'Brien, Jennifer L Walker and 1 more

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A case of abrin toxin poisoning, confirmed via quantitation of L-abrine (N-methyl-L-tryptophan) biomarker.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2014
    Article
  8. Article
  9. Article
  10. Structure of a low-melting-temperature anti-cholera toxin: llama V(H)H domain.Acta crystallographica. Section F, Structural biology and crystallization communications · 2013
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ellen R GoldmanNaval Research Laboratory, Center for Bio/Molecular Science and Engineering, 4555 Overlook Ave SW, Washington, DC 20375, USA. ellen.goldman@nrl.navy.mil
George P Anderson
Dan Zabetakis
Scott Walper
Jinny L Liu
Rachael Bernstein
Alena Calm
James P Carney
Thomas W O'Brien
Jennifer L Walker
Eric A E Garber
United States Naval Research Laboratory · USTetracore (United States) · USU.S. Army Combat Capabilities Development Command Chemical Biological CenterCenter for Food Safety and Applied Nutrition · USNova Research Company (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Llama derived single domain antibodies (sdAb), the recombinantly expressed variable heavy domains from the unique heavy-chain only antibodies of camelids, were isolated from a library derived from llamas immunized with a commercial abrin toxoid preparation. Abrin is a potent toxin similar to ricin in structure, sequence and mechanism of action. The selected sdAb were evaluated for their ability to bind to commercial abrin as well as abrax (a recombinant abrin A-chain), purified abrin fractions, Abrus agglutinin (a protein related to abrin but with lower toxicity), ricin, and unrelated proteins. Isolated sdAb were also evaluated for their ability to refold after heat denaturation and ability to be used in sandwich assays as both capture and reporter elements. The best binders were specific for the Abrus agglutinin, showing minimal binding to purified abrin fractions or unrelated proteins. These binders had sub nM affinities and regained most of their secondary structure after heating to 95 °C. They functioned well in sandwich assays. Through gel analysis and the behavior of anti-abrin monoclonal antibodies, we determined that the commercial toxoid preparation used for the original immunizations contained a high percentage of Abrus agglutinin, explaining the selection of Abrus agglutinin binders. Used in conjunction with anti-abrin monoclonal and polyclonal antibodies, these reagents can fill a role to discriminate between the highly toxic abrin and the related, but much less toxic, Abrus agglutinin and distinguish between different crude preparations.

Indexed as

AbrinAnimalsAntigensCamelids, New WorldCircular DichroismImmunizationPlant LectinsSingle-Domain AntibodiesAbrinabrus agglutininAntigensPlant LectinsSingle-Domain Antibodiesabrinreversible refoldingsingle domain antibody

Identifiers

PMID22174977
PMCPMC3237003
OpenAlexW2023667746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.